Tighe Wilhelmy with Velawcity here to review the 2nd Xarelto bellwether verdict on June 12th, 2017 in the Eastern District of Louisiana for md-2592. The jury decided that Sharyn Orr’s death in 2015 was not the result of Bayer and Johnson & Johnson providing insufficient information about bleeding risks on their blood thinner drug, Xarelto. Plaintiff lawyers said the doctor waited (12) hours before operating because he feared Xarelto would cause Sharyn Orr to bleed out. Defense contended by saying Xarelto’s warnings were adequate and any purported inadequacy didn’t cause her death.
This was the second bellwether victory for the defense with the first verdict taking place on May 3rd. After Bayer’s most recent victory, they proceeded to state they “affirm both the safety and efficacy of Xarelto, and that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine. Needless to say, it’s another disappointing verdict, though (38) bellwethers remain with over 18,000 lawsuits amongst federal and state courts. The third Xarelto bellwether trial is scheduled for August along with Philadelphia bellwethers scheduled to begin in November of 2017.
For more information regarding the Xarelto litigation, including case acquisition, please visit our website or give us a call. Tighe Wilhelmy with Velawcity and thank you for watching.